All In Biotech

NDA 022276 · Hikma Intl Pharms

Nicardipine Hydrochloride In 0.9% Sodium Chloride

Nicardipine Hydrochloride · Intravenous, Injection

Last checked: Nov 20, 2026Latest source record: Jun 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Jul 24, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

47

10 Phase 3, 4 recruiting

FAERS reports

4,421

4,266 serious, 591 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 8, 2025.

1.1 Hypertension Nicardipine hydrochloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits [see Dosage and Administration (2.6)].

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE · NICARDIPINE HYDROCHLORIDE 40MG/200ML (0.2MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
  • NICARDIPINE HYDROCHLORIDE · NICARDIPINE HYDROCHLORIDE 25MG/10ML (2.5MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE · NICARDIPINE HYDROCHLORIDE 20MG/200ML (0.1MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicardipine" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • acute kidney injury252
  • off label use216
  • premature baby209
  • drug ineffective198
  • foetal exposure during pregnancy198
  • maternal exposure during pregnancy187
  • hypotension175
  • drug interaction167
  • hypertension167
  • pyrexia123
  • premature delivery109
  • vomiting108

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200423
200515
2006108
200797
200858
200977
201054
201152
2012126
201397
2014105
2015140
2016159
2017248
2018358
2019288
2020235
2021313
2022385
2023390
2024410
2025451
2026231

Recalls

1 FDA enforcement reports for this application.

  • May 13, 2013 · Class III · Terminated

    Failed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D)

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 549 on PubMed

Sponsor: Hikma Intl Pharms · Also marketed as Nicardipine Hydrochloride

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.